PANBELA THERAPEUTICS INC (PBLA) Stock Analyst Earnings Estimates
NASDAQ:PBLA - Nasdaq - US69833W4042 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 389.44% | N/A 194.12% | N/A 183.56% | N/A 34.84% | ||||||||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A -11.06% | N/A -13.41% | N/A 2.36% | N/A 45.33% | N/A 175.95% | N/A | N/A | |
| EBIT YoY % growth | -3.45M | -5.44M -57.68% | -5.17M 4.96% | -6.01M -16.25% | -3.89M 35.27% | -4.32M -11.05% | -5.75M -33.10% | -10.01M -74.09% | -34.09M -240.56% | N/A 30.03% | N/A -9.09% | N/A -30.30% | N/A -11.01% | N/A 101.19% | N/A 25,070.07% | N/A 274.04% | N/A 39.45% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -25.83 99.85% | -5,796.00 -22,339.02% | N/A 96.41% | N/A 83.13% | N/A 11.53% | N/A 90.86% | N/A 109.35% | N/A 2,146.15% | N/A 180.65% | N/A 29.23% |
All data in USD
| Q3 / 24 | Q4 / 24 | |
|---|---|---|
| EPS Q2Q % growth | -1.22 97.72% | -1.12 95.48% |
| Revenue Q2Q % growth | ||
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -6.816M 13.18% | -6.884M -43.90% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2024 Q2Q % growth | -1.47 99.08% | -1.34 | -0.13 | -10.01% |
| Q1 2024 Q2Q % growth | -2.28 99.42% | -1.51 | -0.77 | -51.03% |
| Q4 2023 Q2Q % growth | 99.27% | -24.83 | % | |
| Q3 2023 Q2Q % growth | -53.80 78.65% | -42.02 | -11.78 | -28.02% |
| Q2 2023 Q2Q % growth | -159.08 91.22% | -95.98 | -63.10 | -65.74% |
| Q1 2023 Q2Q % growth | -390.00 -20.37% | -328.44 | -61.56 | -18.74% |
| Q4 2022 Q2Q % growth | -3,408.00 -32,669.23% | -2,267.46 | -1,140.54 | -50.30% |
| Q3 2022 Q2Q % growth | -252.00 -3,837.50% | -269.28 | 17.28 | 6.42% |
| Q2 2022 Q2Q % growth | -1,812.00 -20,490.91% | -310.08 | -1,501.92 | -484.37% |
| Q1 2022 Q2Q % growth | -324.00 -140,769.57% | -312.12 | -11.88 | -3.81% |
| Q4 2021 Q2Q % growth | -10.40 -11,455.56% | -7.34 | -3.06 | -41.61% |
| Q3 2021 Q2Q % growth | -6.40 -2,947.62% | -9.38 | 2.98 | 31.80% |
| Q2 2021 Q2Q % growth | -8.80 | -7.21 | -1.59 | -22.08% |
| Q1 2021 Q2Q % growth | -0.23 | -0.11 | -0.12 | -104.99% |
| Q4 2020 Q2Q % growth | -0.09 | -0.17 | 0.08 | 46.52% |
| Q3 2020 Q2Q % growth | -0.21 | -0.12 | -0.09 | -71.57% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 1.06% | -1878.86% | 0.84% | -1883.12% |
| Revenue | N/A | N/A | N/A | N/A |